Vidac Pharma Holding Plc | Finanzwire

Basculer en Français

8295	Companies
114831	Keywords
55272	Articles
62429	Press releases

Headlines Articles Press releases Vidac Pharma Holding Plc

Home
Companies
Vidac Pharma Holding Plc

BRIEF

published on 11/20/2024 at 09:21, 1 day 1 hour ago

Vidac Pharma Granted Key Patent by USPTO

Clinical Trials Cancer Treatment USPTO Patent Vidac Pharma Hexokinase-2
PRESS RELEASE

published on 11/20/2024 at 09:16, 1 day 1 hour ago

Original-Research: Vidac Pharma Holding Plc (von Sphene Capital GmbH): Buy
Update report on Vidac Pharma Holding Plc by Sphene Capital GmbH highlighting the significant patent protection granted by the USPTO for its cancer products, leading to a Buy recommendation with a target price of EUR 4.90

Investment Recommendation USPTO Patent Sphene Capital Vidac Pharma Cancer Products
BRIEF

published on 07/29/2024 at 12:31, 3 months 22 days ago

Sphene Capital Reaffirms 'Buy' Rating for Vidac Pharma Holding

BUY Rating Cancer Therapy Sphene Capital Vidac Pharma VDA-1275
PRESS RELEASE

published on 07/29/2024 at 12:26, 3 months 22 days ago

Original-Research: Vidac Pharma Holding Plc (von Sphene Capital GmbH): Buy
Update report by Sphene Capital GmbH highlights promising results of VDA-1275 study by Vidac Pharma Holding Plc in cancer treatment. Buy recommendation maintained with EUR 4.90 target price

Cancer Treatment Sphene Capital GmbH Vidac Pharma Holding VDA-1275 Study EUR 4.90 Target Price
BRIEF

published on 06/12/2024 at 14:41, 5 months 8 days ago

Vidac Pharma Holding Plc: Research Initiation by Sphene Capital GmbH with a Buy Rating

Oncology BUY Rating Biopharmaceutical Clinical-stage Vidac Pharma
PRESS RELEASE

published on 06/12/2024 at 14:36, 5 months 8 days ago

Original-Research: Vidac Pharma Holding Plc (von Sphene Capital GmbH): Buy
Sphene Capital initiates coverage on Vidac Pharma Holding Plc with a Buy rating and a price target of EUR 4.90. Vidac Pharma focuses on reversing cancer cell metabolism for oncology treatments

BUY Rating Sphene Capital GmbH Vidac Pharma Holding Plc Cancer Cell Metabolism Oncology Treatments

Accesswire

Published on 11/21/2024 at 10:03, 35 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 38 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 38 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours 3 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 13 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 10:04, 34 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 36 minutes ago

Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 38 minutes ago

Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 38 minutes ago

Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV
Published on 11/21/2024 at 09:01, 1 hour 37 minutes ago

Original-Research: Netfonds AG (von NuWays AG): Buy

Les Echos

Published on 11/21/2024 at 06:58, 3 hours 40 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 18 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 16 hours 53 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 16 hours 53 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 2 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE